Tag: pyrrolobenzodiazepine
ADC Therapeutics and Mitsubishi Tanabe Pharma Sign Exclusive License Agreement to...
ADC Therapeutics and Mitsubishi Tanabe Pharma Corporation have signed an exclusive license agreement for the development and commercialization of loncastuximab tesirine (ADCT-402; Zynlonta®; ADC...
REGN3124-PBD a Novel EGFRvIII-selective ADC Shows Promise Against Glioblastoma Multiforme Patient-derived...
Glioblastoma Multiforme (GBM) is a highly aggressive primary malignant brain tumor with few specific molecular targets and poor therapeutic outcomes. The disease accounts for...
European Commission Grants Orphan Drug Designation to Loncastuximab Tesirine
The European Commission has granted Orphan Drug Designation to loncastuximab tesirine (Zynlonta®; ADC Therapeutics); previously known as ADCT-402, a CD19-targeted ADC, for the treatment...
LegoChem and Iksuda Expand License Agreement
Iksuda Therapeutics and LegoChem Biosciences have confirmed that they have expanded their research collaboration and License Agreement to explore additional ADC programs. The collaboration...
Results of LOTIS-2 Study of Loncastuximab Tesirine Shows Substantial Single-agent Activity,...
Results of LOTIS-2, a multicenter, open-label, single-arm Phase II clinical trial evaluating the safety and efficacy of single-agent loncastuximab tesirine-lpyl (Zynlonta™; ADC Therapeutics; previously...
Enrollment Completed for Pivotal Phase II Clinical Trial of Camidanlumab Tesirine...
Enrolment for the pivotal Phase II clinical trial (NCT04052997) evaluating the efficacy and safety of camidanlumab tesirine (formerly ADCT-301) in patients with relapsed or...
CStone Pharmaceuticals and LegoChem Biosciences Enter Global Licensing Agreement for...
Suzhou (China-) based CStone Pharmaceuticals and LegoChem Biosciences have signed a global licensing agreement in which CStone acquires exclusive rights for development and commercialization...
Preclinical Study Supports Continued Evaluation of CD25-targeted ADC in Selected Advanced...
Preclinical data for camidanlumab tesirine (formerly ADCT-301; ADC Therapeutics), published in the Journal for ImmunoTherapy of Cancer, the online journal of the Society for...
FDA Lifts Partial Clinical Hold on Pivotal Phase II Clinical Trial...
Earlier this week the U.S. Food and Drug Administration (FDA) lifted a partial clinical hold on the pivotal Phase II clinical study of camidanlumab...
Loncastuximab Tesirine Shows Early Promise in Patients with Relapsed/Refractory B-cell Non-Hodgkin...
Loncastuximab tesirine, also known as ADCT-402, an investigational antibody-drug conjugate being developed by ADC Therapeutics, showed signs of clinical activity in patients with relapsed/refractory...
